Anorexia Nervosa - Pipeline Insight, 2024

This “Anorexia Nervosa - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anorexia Nervosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anorexia Nervosa: Understanding

Anorexia Nervosa: Overview

Anorexia nervosa is an eating disorder defined by restriction of energy intake relative to requirements, leading to a significantly low body weight. Patients will have an intense fear of gaining weight and distorted body image with the inability to recognize the seriousness of their significantly low body weight.Anorexia nervosa is more common in females than males. Onset is late adolescence and early adulthood. Lifetime prevalence is 0.3% to 1% (European studies have demonstrated a prevalence of 2% to 4%), irrespective of culture, ethnicity, and race. Risk factors for eating disorders include childhood obesity, female sex, mood disorders, personality traits (impulsivity and perfectionism), sexual abuse, or weight-related concerns from family or peer environments. Studies demonstrate biological factors play a role in the development of anorexia nervosa in addition to environmental factors. Genetic correlations exist between educational attainment, neuroticism, and schizophrenia. Patients with anorexia nervosa have altered brain function and structure there are deficits in neurotransmitters dopamine (eating behavior and reward) and serotonin (impulse control and neuroticism), differential activation of the corticolimbic system (appetite and fear), and diminished activity among the front striatal circuits (habitual behaviors).

Anorexia nervosa is a serious eating disorder characterized by low body weight, fear of gaining weight, and distorted perception of body weight. Diagnosis involves physical exams, measuring height and weight, checking vital signs, and electrocardiograms. Treatment is managed by an interprofessional team and includes ongoing therapy, nutrition education, and specialized eating disorder programs. In severe cases, feeding through a tube may be required. Early diagnosis and treatment are important for a positive outcome.

Treatment for anorexia nervosa involves a combination of psychotherapy, supervised weight gain, and nutritional counseling. Inpatient treatment may be necessary for patients with existing psychiatric disorders requiring hospitalization, high suicide risk, and lack of support system, medical instability, severe anorexia, or persistent purging behaviors. Refeeding syndrome, a potential complication, should be carefully monitored. Pharmacotherapy is not initially used, but acutely ill patients who do not respond to initial treatment may be prescribed olanzapine. Family-based psychotherapy is beneficial for pediatric patients. Outpatient treatment includes intensive therapy and partial hospitalization. Patients with anorexia nervosa can find it challenging to engage in treatment, and family and friends' support is crucial for recovery and preventing relapses.

“Anorexia Nervosa - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Anorexia Nervosa pipeline landscape is provided which includes the disease overview and Anorexia Nervosa treatment guidelines. The assessment part of the report embraces, in depth Anorexia Nervosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anorexia Nervosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia Nervosa R&D. The therapies under development are focused on novel approaches to treat/improve Anorexia Nervosa.

Anorexia Nervosa Emerging Drugs Chapters

This segment of the Anorexia Nervosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anorexia Nervosa Emerging Drugs

Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company is conducting a Phase II clinical trial investigating the efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa.

Anorexia Nervosa: Therapeutic Assessment

This segment of the report provides insights about the different Anorexia Nervosa drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anorexia Nervosa

There are approx. 3+ key companies which are developing the therapies for Anorexia Nervosa. The companies which have their Anorexia Nervosa drug candidates in the most advanced stage, i.e. Phase III include, COMPASS Pathways.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anorexia Nervosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anorexia Nervosa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anorexia Nervosa therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia Nervosa drugs.

Anorexia Nervosa Report Insights

• Anorexia Nervosa Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anorexia Nervosa Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anorexia Nervosa drugs?
• How many Anorexia Nervosa drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anorexia Nervosa?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anorexia Nervosa therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anorexia Nervosa and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• COMPASS Pathways
• Biomind Labs

Key Products

• Psilocybin
• Ibogaine

This product will be delivered within 2 business days.